Predictive biomarkers for MS

Stanford UniversityandPfizer Inc.researchers have reported that levels of IL-7 could help predictwhich multiple sclerosis patients will not respond to interferon-b therapy.1 Serum analysis of IL-7 together with a second marker identified last year by the Stanford team, IL-17F, which was only able to identify about 10% of nonresponders on its own, could predict up to one-third of nonresponders.

Stanford has spun out Atreca Inc. to develop predictive blood tests based on the findings.

Interferon-b (IFNB; IFN-b) is the standard first-line treatment for patients with relapsing-remitting multiple sclerosis (RRMS). Up to 25% of patients do not respond to the drugs, and treatment can even exacerbate the disease in some cases.

"The ability to identify patients who will versus

Read the full 1140 word article

How to gain access

Continue reading with a
two-week free trial.